Published online 2013 June 7. doi: 10.3748/wjg.v19.i21.3199.
Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Qing-Lei Zeng, Ji-Yuan Zhang, Zheng Zhang, Li-Feng Wang and Fu-Sheng Wang.
Download PDF
Abstract
Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Qing-Lei Zeng, Ji-Yuan Zhang, Zheng Zhang, Li-Feng Wang and Fu-Sheng Wang.
Download PDF
Abstract
Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with this regimen. SVR rates are approximately 80% in patients with hepatitis C virus (HCV) genotype 2, 3, 5 and 6 and 40%-50% in patients with genotype 1 and 4. Therefore, strategies to improve SVR rates have been an important issue for clinical physicians. Several direct acting antiviral agents (DAAs) have significantly higher SVR rates when combined with pegIFN-α and RBV than pegIFN-α and RBV alone. Treatments containing DAAs have several advantages over the previous SOC, including higher specificity and efficacy, shorter treatment durations, fewer side effects, and oral administration. Based on these advantages, treatment with pegIFN-α and RBV plus telaprevir or boceprevir has become the current SOC for patients with genotype 1 HCV infection. However, many patients are either not eligible for therapy or decline treatment due to coexisting relative or absolute contraindications as well as an inability to tolerate the hematological side effects and adverse events caused by the new SOC. These factors have contributed to the advent of pegIFN-α-free regimens. The newest therapeutic regimens containing sofosbuvir and ABT-450 have shown promising results. In this review, we summarize the development of anti-HCV agents and the clinical efficacy of sofosbuvir and ABT-450-based therapies as well as the potential for future HCV studies.
Keywords: Sofosbuvir, ABT-450, Hepatitis C virus, Antiviral therapy, Sustained virologic response
Core tip: We are entering an era in which the development of antiviral agents and successful treatment of chronic hepatitis C is rapidly escalating. In this review, we have summarized the history of anti-hepatitis C virus (HCV) agents from interferon-α (IFN-α) to the latest sofosbuvir- and ABT-450-based therapies. Although a new generation of direct acting anti-HCV agents has largely improved the sustained virologic response rates of patients, many unmet needs and questions remain, such as IFN-free regimens for difficult to treat patients, avoidance of cross-resistance, the role of interleukin-28B status as well as the management of some advanced and co-infected patients.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is currently a major global health problem that affects 160 million people worldwide and is one of the main causes of chronic liver cirrhosis and hepatocellular carcinoma[1,2]. Compared with the former standard of care (SOC), the current SOC, consisting of peginterferon (pegIFN)-α and ribavirin (RBV) plus telaprevir or boceprevir, achieves higher rates of sustained virologic response (SVR), which is defined as undetectable HCV RNA in the serum for 24 wk after the end of treatment. SVR is associated with a better outcome for chronic hepatitis C (CHC) patients[3,4]. However, not all patients can achieve SVR[5,6]. In addition, triple therapy has many side effects and contraindications that result in a number of eligible patients refusing therapy[7,8].
Based on these complications, pegIFN-α-free regimens could be an alternative for some patients. Several pegIFN-α-free regimens containing sofosbuvir and ABT-450 have shown high SVR rates with only 12 wk of treatment and mild adverse events. These regimens have the potential to be the newest SOC for CHC in the near future. Here, we summarize the clinical development history of anti-HCV agents as well as recent studies of the efficacy and adverse event profile of sofosbuvir and ABT-450 regimens. We also discuss the future focus for HCV studies
BRIEF DEVELOPMENT HISTORY OF ANTI-HCV AGENTS
IFN era
Anti-HCV therapy is the backbone for the treatment of CHC. Since the late 1980s, IFN-α has gradually become the core of antiviral treatment[9-13]. However, IFN-α monotherapy achieved suboptimal efficacy until combined with RBV[14-22] (Figure 1). PegIFN-α has a higher plasma concentration and half-life than interferon, which results in an improved SVR rate as well as improved patient compliance as the pegylated form can be injected once weekly[23-25]. Higher SVR rates were achieved with combination therapy of pegIFN plus RBV than with pegIFN monotherapy, which has become the SOC during the past decade[26,27]. Meanwhile, the true meaning of SVR was unclear until a large cohort study demonstrated that patients who achieved SVR could be considered cured[28]. Unfortunately, not all patients, especially those infected with genotype 1 and 4 HCV could achieve SVR with the SOC. Furthermore, side effects, long-term treatment, contraindications and poor compliance all spurred the development of new agents with shorter treatment durations, fewer contraindications, oral administration, higher specificity, and fewer side effects.
Figure 1
Figure 1
Brief development history of the anti-hepatitis C virus agents. HCV: Hepatitis C virus; IFN-α: Interferon-α; SVR: Sustained virologic response; pegIFN-α: Peginterferon-α.
Era of direct acting antiviral agents
HCV is classified in the genus hepacivirus of the family flaviviridae. Once the virus is released into the cell, the viral polyprotein is translated and cleaved by host proteases and the viral NS3-4A protease into ten mature proteins. Next, viral RNA is replicated into progeny RNA by the viral NS5B polymerase. Another viral protein, HCV NS5A, is indispensable for viral replication and assembly and could be a nonenzymatic target for therapeutics. With the structures of NS3/4A protease and NS5B polymerase solved and the rapid development of different cell culture models and biotechnology[29], HCV research has been flourishing both on the bench and in industry. In particular, intensive efforts have focused on developing direct acting antiviral agents (DAAs) that can block the activity of viral enzymes.
The serine protease inhibitors telaprevir and boceprevir, approved by the United States Food and Drug Administration in 2011, were the first and currently only DAA to make it to the clinic. Telaprevir is a linear peptidomimetic HCV NS3/4A serine protease inhibitor, and boceprevir is a protease inhibitor that binds to the HCV NS3 active site. Treatment regimens consisting of telaprevir or boceprevir plus pegIFN-α and RBV had significantly higher SVR rates in genotype 1 patients and became the SOC thereafter[30-34]. However, this new SOC has more adverse events and a similar treatment duration when compared with the former SOC[35], and monotherapy with telaprevir or boceprevir was shown to be impractical due to the rapid selection of resistant variants. In 2012, preliminary clinical data showed that combination therapy with the NS5A replication complex inhibitor daclatasvir and the NS3 protease inhibitor asunaprevir could also achieve high efficacy rates after 24 wk of treatment[36], especially in prior null responders. These results showed the potential of a pegIFN-free regimen for 24 wk treatment duration. However, some patients in this study experienced viral breakthrough due to resistant variants, which ultimately resulted in treatment failure.
In January 2013, Gane et al[37] and Poordad et al[38] published clinical data on the efficacy of sofosbuvir- (also known as GS-7977) and ABT-450-based oral treatment regimens for 12 wk treatment duration. The results showed that 100% of genotype 2/3 patients and 93%-95% of genotype 1 patients achieved SVR. The sofosbuvir and ABT-450 studies were open-label clinical studies that assessed various combination and dosages of agents in previously treated and previously untreated patients. Sofosbuvir exhibits a higher barrier to resistance than ABT-450 because its target, the NS5B polymerase is highly conserved, and viral fitness is crippled if variants occur in the polymerase active site. Sofosbuvir also exhibits pan-genotypic antiviral activity compared to genotype-specific agents, such as ABT-450, asunaprevir, telaprevir and boceprevir. Although some mild adverse events were observed, these studies validated the feasibility of achieving extremely high SVR rates with a pegIFN-free regimen and a short treatment duration of 12 wk.
General characteristics of representative DAAs
General characteristics of representative DAAs
We summarize representative DAAs from 2011 to January 2013 in Table 1. There have been several treatment evolutions during this timeframe. First, most of these agents were designed for genotype 1 patients, with genotypes 2 and 3 only being considered recently. Second, the treatment period has gradually decreased to 12 wk. Third, dosing frequency has generally improved from three times daily to once daily, which will undoubtedly contribute to better patient compliance. Fourth, combination therapy has gradually shifted away from exclusive combinations with pegIFN-α to trials with and without pegIFN-α to finally pegIFN-α-free regimens. Finally, we found that at least two representative agents were developed from bench to bedside every year. Compared with other DAAs, the sofosbuvir and ABT-450 regimens not only achieve extremely high SVR rates with 12 wk of treatment in treatment-naive patients but are also efficacious in genotype 2 and 3 patients without the need for pegIFN-α.
Representative direct acting antiviral agent from 2011 to January, 2013
| DAA | HCV genotype | Course of DAA (wk) | Course of therapy (wk) | Dose | With or without pegIFN-α | Published year | Ref. |
| Telaprevir | 1a/1b/1c/unknown | 12/8 | 20/24/44/48 | 750 mg (tid) | With | 2011 | [30-32] |
| Boceprevir | 1a/1b/unknown | 24/32/44 | 28/36/48 | 800 mg (tid) | With | 2011 | [33-34] |
| Daclatasvir | 1a/1b | 24 | 24 | 60 mg (qd) | With or without | 2012 | [36] |
| Asunaprevir | 1a/1b | 24 | 24 | 600 mg (bid) | With or without | 2012 | [36] |
| Sofosbuvir | 1/2/3 | 8/12 | 8/12 | 400 mg (qd) | Without | 2013 | [37] |
| ABT-450 | 1a/1b | 12 | 12 | 250/150 mg (qd) | Without | 2013 | [38] |
qd: Once daily; bid: Twice daily; tid: Thrice daily; DAA: Direct acting antiviral agent; HCV: Hepatitis C virus; pegIFN-α: Peginterferon-α.
CLINICAL EFFICACY OF SOFOSBUVIR AND ABT-450
Sofosbuvir is a direct acting nucleotide polymerase inhibitor[39], and ABT-450 is a potent macrocyclic HCV NS3 protease inhibitor. Both have been developed as oral therapies for the treatment of chronic HCV infection. Phosphorylated nucleotide analogues, such as sofosbuvir, are converted within the host hepatocyte to the active nucleoside triphosphate, which competes with natural nucleotides, thereby terminating RNA replication in the nascent viral genome. Sofosbuvir acts as a nonobligate chain terminator, targeting the highly conserved active site of the HCV-specific NS5B polymerase[38]. The mechanism of action of NS3 protease inhibitors has been thoroughly reviewed elsewhere[35]. As a potent inhibitor of CYP3A4 (the primary enzyme involved in first-pass metabolism of most protease inhibitors), ritonavir can increase the plasma concentration and half-life of ABT-450, decrease the emergence of resistance mutations in the NS3 gene, and permit once-daily dosing of ABT-450[38,40,41].
Clinical efficacy of sofosbuvir-based therapy
Clinical efficacy of sofosbuvir-based therapy
Gane et al[37] published an open-label clinical trial of 95 previously untreated HCV genotype 1/2/3 patients and genotype 1 null responders (Table 2). The patients were divided into 8 groups: sofosbuvir monotherapy and sofosbuvir plus RBV therapy with or without pegIFN-α for 8 or 12 wk. The results showed that 100% of previously untreated genotype 2/3 patients achieved SVR based on sofosbuvir plus RBV. For previously untreated genotype 1 patients, the SVR rate was 84%. Unfortunately, the SVR rate was only 10% for genotype 1 patients who had no response to previous therapy. These results indicate that genotype 2/3 untreated patients can be completely cured with 12 wk of sofosbuvir plus RBV therapy alone.
Table 2
Table 2
Overview of 95 hepatitis C patients under sofosbuvir regimen
Table 2
Table 2
Overview of 95 hepatitis C patients under sofosbuvir regimen
| Group | n | Genotype (n) | Status before treatment | Therapeutic schedule | SVR rate |
| 1 | 10 | 2/3 (4/6) | Untreated | Sofosbuvir + RBV 12 wk | 100% |
| 2 | 9 | 2/3 (3/6) | Untreated | (Sofosbuvir + RBV 12 wk) + pegIFNα-2a 4 wk | 100% |
| 3 | 10 | 2/3 (4/6) | Untreated | (Sofosbuvir + RBV 12 wk) + pegIFNα-2a 8 wk | 100% |
| 4 | 11 | 2/3 (4/7) | Untreated | Sofosbuvir + RBV + pegIFNα-2a 12 wk | 100% |
| 5 | 10 | 2/3 (3/7) | Untreated | Sofosbuvir 12 wk | 60% |
| 6 | 10 | 2/3 (0/10) | Untreated | Sofosbuvir + RBV + pegIFNα-2a 8 wk | 100% |
| 7 | 10 | 1a/1b (9/1) | No response to prior therapy | Sofosbuvir + RBV 12 wk | 10% |
| 8 | 25 | 1a/1b (22/3) | Untreated | Sofosbuvir + RBV 12 wk | 84% |
The dose of sofosbuvir is 400 mg (qd), peginterferon-α (pegIFN-α)-2a is 180 μg (qw), ribavirin (RBV) is 500 mg (bid) for patients with body weight < 75 kg, and RBV is 600 mg (bid) for patients with body weight > 75 kg. qd: Once daily; bid: Twice daily; qw: Once weekly; SVR: Sustained virologic response.
Clinical efficacy of ABT-450-based therapy
Clinical efficacy of ABT-450-based therapy
Poordad et al[38] published an open-label, phase 2a clinical trial of 50 genotype 1 patients, including untreated patients and patients with no or partial response to prior therapy (Table 3). The patients were divided into 3 groups. Patients received a combination of ABT-333 (a nonnucleoside NS5B polymerase inhibitor), RBV and ritonavir plus two different dosages of ABT-450 for 12 wk. The results showed that 93% and 95% of previously untreated genotype 1 patients achieved SVR. Furthermore, 47% prior null and partial responders achieved SVR. These results indicate that almost all untreated patients with genotype 1 can achieve SVR with ABT-450-based regimens, and null and partial responders can achieve higher SVR rates than previously possible.
Table 3
Table 3
Overview of 50 hepatitis C patients under ABT-450 regimen
Table 3
Table 3
Overview of 50 hepatitis C patients under ABT-450 regimen
| Group | n | Genotype (n) | Status before treatment | Therapeutic schedule | Usage | SVR rate2 |
| 1 | 19 | 1a/1b (17/2) | Untreated | ABT-450 + ritonavir + ABT-333 + RBV 12 wk | ABT-450, 250 mg (qd) | 95% |
| Ritonavir, 100 mg (qd) | ||||||
| ABT-333, 400 mg (bid) | ||||||
| RBV, 1000 or 1200 mg/d1 | ||||||
| 2 | 14 | 1a/1b (11/3) | Untreated | ABT-450 + ritonavir + ABT-333 + RBV 12 wk | ABT-450, 150 mg (qd) | 93% |
| Ritonavir + ABT-333 + RBV Ditto | ||||||
| 3 | 17 | 1a/1b (16/1) | No or partial response to prior therapy | ABT-450 + ritonavir + ABT-333 + RBV 12 wk | ABT-450, 150 mg (qd) | 47% |
| Ritonavir + ABT-333 + RBV Ditto |
1Body weight < 75 kg, 1000 mg/d, divided into doses of 400 and 600 mg, bid; Body weight ≥ 75 kg, 1200 mg/d, 600 mg, bid;
2Sustained virologic response (SVR) in this study was defined as an
ADVERSE EVENTS OF SOFOSBUVIR AND ABT-450 REGIMENS
ADVERSE EVENTS OF SOFOSBUVIR AND ABT-450 REGIMENS
Both sofosbuvir and ABT-450 regimens have various adverse events (Table 4). The most frequent adverse events observed with sofosbuvir-based therapies were headache, fatigue, insomnia, nausea, rash, and anemia[37,42]. For ABT-450-based therapies, the most frequent adverse events were fatigue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting. Some laboratory abnormalities were also observed during the treatment period, including anemia for sofosbuvir-based treatment and hyperbilirubinemia for ABT-450-based therapy. Some laboratory abnormalities were more common among patients receiving pegIFNα-2a. Most adverse events and abnormalities were mild, and none led to treatment interruption.
Table 4
Table 4
Major adverse events during sofosbuvir and ABT-450 regimens
Major adverse events during sofosbuvir and ABT-450 regimens
Major adverse events during sofosbuvir and ABT-450 regimens
| Adverse events | Sofosbuvir regimen | ABT-450 regimen1 |
| Headache | 32%-90% | 14%-26% |
| Fatigue | 10%-70% | 35%-47% |
| Insomnia | 10%-67% | 0%-26% |
| Nausea | 0%-44% | 21%-24% |
| Rash | 10%-60% | 6%-21% |
| Anemia | 0%-44% | No data |
| Dizziness | 4%-44% | 5%-29% |
| Myalgia | 0%-40% | No data |
| Diarrhea | 0%-30% | No data |
| Vomiting | No data | 0%-21% |
| Irritability | 0%-36% | No data |
| Pruritus | 0%-33% | 0%-21% |
| Decreased appetite | 0%-50% | No data |
| Upper respiratory tract infection | 0%-20% | No data |
| Arthralgia | 0%-30% | No data |
| Back pain | 0%-22% | No data |
| Pyrexia | 0%-18% | No data |
1Adverse events during ABT-450 regimen were only listed those that occurred in more than 20% of patients.
INTERLEUKIN-28B POLYMORPHISM IN THE SOFOSBUVIR AND ABT-450 ERA
INTERLEUKIN-28B POLYMORPHISM IN THE SOFOSBUVIR AND ABT-450 ERA
Genome-wide association studies have demonstrated that single nucleotide polymorphisms near the interleukin-28B (IL-28B) gene that encodes IFN-λ3 are closely associated with spontaneous and treatment-induced HCV clearance[43-46]. The rs12979860 CC genotype is associated with a two-fold greater SVR rate than the TT genotype in European-American individuals. Similar ratios have been observed in both African-American and Hispanic populations of genotype 1 chronic hepatitis C patients. The presence of the C-allele is always accompanied by higher SVR rates, indicating that this allele may favor the clearance of HCV. In studies of sofosbuvir and ABT-450, five groups achieved SVR rates of 100%, independent of IL-28B status (Table 5). Therefore, lower SVR rates may not be primarily due to IL-28B genotypes. Instead, these patients may have acquired resistant variants during treatment. However, it should be noted that the sample size of these studies too small to reach a definitive conclusion on the role of IL-28B. Whether IL-28B genotype will be a predictive marker for treatment response with the new drug regimens requires further investigation with large sample sizes.
Table 5
Table 5
Interleukin-28B polymorphism in sofosbuvir and ABT-450 era
Table 5
Table 5
Interleukin-28B polymorphism in sofosbuvir and ABT-450 era
| Group | Status before treatment | IL-28B CC (n) | IL-28B CT (n) | IL-28B TT (n) | SVR rate |
| Sofosbuvir | |||||
| 1 | Untreated | 5 | 4 | 1 | 100% |
| 2 | Untreated | 4 | 4 | 1 | 100% |
| 3 | Untreated | 4 | 4 | 2 | 100% |
| 4 | Untreated | 4 | 5 | 2 | 100% |
| 5 | Untreated | 2 | 6 | 2 | 60% |
| 6 | Untreated | 3 | 6 | 1 | 100% |
| 7 | No response to prior therapy | 2 | 5 | 3 | 10% |
| 8 | Untreated | 11 | 12 | 2 | 84% |
| ABT-450 | |||||
| 1 | Untreated | 10/9 | 7/7 | 2/2 | 95% |
| 2 | Untreated | 5/4 | 7/7 | 2/2 | 93% |
| 3 | No or partial response to prior therapy | 0/0 | 12/6 | 5/2 | 47% |
IL-28B: Interleukin-28B; SVR: Sustained virologic response.
PERSPECTIVES
PERSPECTIVES
Genotype 1 patients with no or partial response to prior therapy will be the focus of future studies
Currently, the highest SVR rate observed in genotype 1 patients who have no response to prior therapy is 90%, which was achieved with daclatasvir and asunaprevir-based therapy (Table 6). SVR rates in this patient population treated with telaprevir and boceprevir regimens were only 33% and 52%, respectively, which was significantly inferior to the rates in treatment-naive patients.
Sofosbuvir plus RBV has achieved an excellent SVR rate in untreated genotype 1 patients compared with genotype 1 patients who had no response to previous treatment. While the ABT-450 regimen achieved high efficacy in genotype 1 patients with no or partial response to prior treatment, the SVR rate was still less than 50%. All of the above-mentioned results suggest that genotype 1 patients with no or partial response should be the focus of further investigation. Furthermore, genotype 1a patients have more opportunities to develop resistance to the DAAs combination from Poordad et al[38]. Genotype 1a accounts for 89%, 8 out of 9 patients with virologic failure in group 3 who have been analyzed for the presence of resistance-associated variants. The genetic barrier to resistance of protease inhibitors is relatively lower for subtype 1a because this subtype only requires one nucleotide substitution to generate resistance, whereas the 1b virus requires two. Accordingly, genotype 1a patients may be more difficult to treat in new DAAs era.
Table 6
Sofosbuvir plus RBV has achieved an excellent SVR rate in untreated genotype 1 patients compared with genotype 1 patients who had no response to previous treatment. While the ABT-450 regimen achieved high efficacy in genotype 1 patients with no or partial response to prior treatment, the SVR rate was still less than 50%. All of the above-mentioned results suggest that genotype 1 patients with no or partial response should be the focus of further investigation. Furthermore, genotype 1a patients have more opportunities to develop resistance to the DAAs combination from Poordad et al[38]. Genotype 1a accounts for 89%, 8 out of 9 patients with virologic failure in group 3 who have been analyzed for the presence of resistance-associated variants. The genetic barrier to resistance of protease inhibitors is relatively lower for subtype 1a because this subtype only requires one nucleotide substitution to generate resistance, whereas the 1b virus requires two. Accordingly, genotype 1a patients may be more difficult to treat in new DAAs era.
Table 6
Outcome of representative direct acting antiviral agent-based therapy for genotype 1 null responders
Table 6
Table 6
Outcome of representative direct acting antiviral agent-based therapy for genotype 1 null responders
| Authors | n | Therapeutic schedule | SVR rate |
| Zeuzem et al[32] | 37 | (pegIFN-α2a + RBV) 4 wk + (pegIFN-α2a + RBV + telaprevir) 12 wk + (pegIFN-α2a + RBV) 32 wk | 33% |
| Bacon et al[33] | 58 | (pegIFN-α2b + RBV) 4 wk + (pegIFN-α2b + RBV + boceprevir) 44 wk | 52% |
| Lok et al[36] | 11 | Daclatasvir + asunaprevir 24 wk | 36% |
| Lok et al[36] | 10 | Daclatasvir + asunaprevir + pegIFN-α2a + RBV 24 wk | 90% |
| Gane et al[37] | 10 | Sofosbuvir + RBV 12 wk | 10% |
| Poordad et al[38] | 7 | ABT-450 + ritonavir + ABT-333 + RBV 12wk | 43% |
pegIFN-α: Peginterferon-α; SVR: Sustained virologic response; RBV: Ribavirin.
DAA combinations with less cross-resistance may be the solution for genotype 1 patients with no or partial response to prior therapy
DAA combinations with less cross-resistance may be the solution for genotype 1 patients with no or partial response to prior therapy
Although it has not been investigated in a head-to-head study, genotype 1 patients with no or partial response to prior therapy have different SVR rates (10% vs 90%) with different DAA combinations (Table 6)[37,38], indicating that different DAA combinations might be important to successfully treating these types of patients. Various combinations of DAAs are now under investigation[47,48]. However, why a particular combination may lead to an improved SVR rate in these patients remains unclear. It is possible that adding another DAA could complement the mechanisms of action of other agents in the regimen as well as decrease the appearance of cross-resistant variants. As Table 6 shows, 90% of genotype 1 patients with no response to prior therapy can achieve SVR[33], suggesting that a potent DAA combined with pegIFN-α and RBV may be one choice for those patients who can endure the adverse events and long period of treatment.
Combinations with less cross-resistance are the goal for the future
Combinations with less cross-resistance are the goal for the future
Various DAA combinations have now been investigated, such as asunaprevir plus daclatasvir; sofosbuvir plus RBV; sofosbuvir plus daclatasvir; faldaprevir plus BI207127; ABT-450/ritonavir plus ABT-333; ABT-450, ritonavir plus ABT-072; miracitabine, danoprevir plus ritonavir; and alisporivir plus RBV[47]. DAA combinations not only have the potential to increase antiviral efficacy but also to reduce the risk of viral breakthrough. When combining DAAs, it is important to consider combinations that have a low propensity for cross-resistance. The genetic barriers to resistance of DAAs appear to be an important factor during the development of resistance. When two agents with a low genetic barrier to resistance are combined, breakthrough occurs more quickly[49]. Adding on pegIFN-α or RBV[36] as well as nucleoside analogues with a higher genetic barrier might be better tactics for overcoming resistance[37,50]. For example, 90% of difficult-to-treat patients can achieve SVR with a combination of daclatasvir, asunaprevir, pegIFN-α2a and RBV for 24 wk of treatment[36]. Furthermore, 84%-100% of patients can achieve SVR with a combination of sofosbuvir plus RBV for 12 wk of therapy[37].
PegIFN-α: To be with or not to be with
PegIFN-α: To be with or not to be with
Whether or not to include pegIFN-α is a key issue in the DAA era. Several years ago, many hepatologists believed that HCV treatment would be IFN free. Now, however, the ability to do away with IFN is not so clear, especially in some difficult-to-treat patients. Although not compared in a head-to-head study, the SVR rate was relatively lower in refractory patients treated with a pegIFN-free regimen, as shown in Table 6. This information indicates that IFN-free regimens may be available for easy-to-treat patients in the near future, whereas IFN might be necessary for difficult-to-treat patients.
Role of IL-28B in reducing treatment duration
Role of IL-28B in reducing treatment duration
In Tables 2 and 5, groups 4 and 6 differ with respect to treatment duration (12 and 8 wk, respectively). In group 4, 81% (9/11) of patients were genotype CC or CT. In group 6, 90% (9/10) of patients were genotype CC or CT. It will be interesting to investigate whether IL-28B polymorphisms could predict treatment duration in the DAA era, especially in patients with the potential to reduce the treatment course.
Other aspects
Other aspects
In addition to above-mentioned situations, results from group 5 patients who received sofosbuvir monotherapy suggested the crucial role of RBV in maintaining an antiviral response (Table 2). However, the exact mechanism by which RBV contributes to SVR in the DAA era remains uncertain. Another area of important research in the future will likely be treatment of patients with cirrhosis, and hepatitis B virus and human immunodeficiency virus co-infected patients. Although the sofosbuvir- and ABT-450-based therapies were well tolerated, the safety profile of other combination treatments remains to be seen.
CONCLUSION
CONCLUSION
A series of clinical trials have demonstrated that we are currently experiencing a “watershed moment” for the treatment of hepatitis C[51,52]. Despite some unresolved questions, the recent achievements demonstrating DAAs as potent new HCV clearing agents with improved SVR rates appear to be encouraging, and it may be possible to cure nearly all HCV-infected patients in the near future.The progress of new anti-HCV agents might indicate that agents with specificity, sensitivity and a high barrier to resistance are the mainstay for conquering pathogen-related disease. Future studies may focus on the improvement of SVR rates in genotype 1 patients who have no or partial response to prior therapy as well as special patient populations, such as those with cirrhosis or co-infected patients. Furthermore, determining an optimal combination therapy with little cross-resistance and few adverse events as well as better understanding the status of IL-28B polymorphism and the potential mechanism of how RBV may synergize with DAAs are also areas of future study.
Footnotes
Footnotes
Supported by Grants from the National Key Basic Research Program of China, No. 2009CB522507, No. 2012CB519005; and Beijing Nova Program of China, No. Z12110702512071
P- Reviewers Estrabaud E, Quer J S- Editor Wen LL L- Editor A E- Editor Li JY
hepatitis C virus RNA level of less than 25 IU/mL 12 wk after treatment. qd: Once daily; bid: Twice daily; RBV: Ribavirin.
1.
2.
3.
4.
5.
6.
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97-103.[PubMed] [DOI]
7.
8.
9.
10.
11.
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-1506.[PubMed] [DOI]
12.
Thomson BJ, Doran M, Lever AM, Webster AD. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet. 1987;1:539-541.[PubMed]
13.
Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393-397.[PubMed]
14.
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.[PubMed] [DOI]
15.
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-1499.[PubMed] [DOI]
16.
17.
Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis. 1995;27:325-329.[PubMed]
18.
Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 1995;23 Suppl 2:8-12.[PubMed]
19.
Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol. 1996;28:505-511.[PubMed]
20.
Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Idéo G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat. 1997;4:185-191.[PubMed]
21.
22.
Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-87.[PubMed]
23.
24.
25.
26.
27.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.[PubMed]
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Pilot-Matias T, Tripathi R, Dekhtyar T, Menon R, Gaultier I, Cohen D, Podsadecki T, Bernstein B, Collins C. Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450. J Hepatol. 2011;54 Suppl 1:S485-S486. [DOI]
42.
Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol. 2012;Nov 23; Epub ahead of print.[PubMed] [DOI]
43.
44.
45.
46.
47.
48.
49.
Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2012;55:749-758.[PubMed] [DOI]
50.
McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008;52:1604-1612.[PubMed] [DOI]
51.
No comments:
Post a Comment